EA202091739A1 - Генная терапия против тазово-плечевой мышечной дистрофии типа 2c - Google Patents
Генная терапия против тазово-плечевой мышечной дистрофии типа 2cInfo
- Publication number
- EA202091739A1 EA202091739A1 EA202091739A EA202091739A EA202091739A1 EA 202091739 A1 EA202091739 A1 EA 202091739A1 EA 202091739 A EA202091739 A EA 202091739A EA 202091739 A EA202091739 A EA 202091739A EA 202091739 A1 EA202091739 A1 EA 202091739A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gene therapy
- pelvic
- dystrophy type
- muscle dystrophy
- shoulder muscle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Abstract
Изобретение относится к векторам генной терапии, таким как векторы AAV, содержащие полинуклеотид, кодирующий -саркогликан (SGCG), и способам использования таких векторов генной терапии для лечения субъектов, страдающих мышечной дистрофией, например тазово-плечевой дистрофией типа 2C (LGMD2C).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624616P | 2018-01-31 | 2018-01-31 | |
PCT/US2019/015779 WO2019152474A1 (en) | 2018-01-31 | 2019-01-30 | Gene therapy for limb-girdle muscular dystrophy type 2c |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091739A1 true EA202091739A1 (ru) | 2021-01-14 |
Family
ID=67478478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091739A EA202091739A1 (ru) | 2018-01-31 | 2019-01-30 | Генная терапия против тазово-плечевой мышечной дистрофии типа 2c |
Country Status (17)
Country | Link |
---|---|
US (1) | US20200360534A1 (ru) |
EP (1) | EP3746100A4 (ru) |
JP (2) | JP7361701B2 (ru) |
KR (1) | KR20200115585A (ru) |
CN (1) | CN111818946A (ru) |
AR (1) | AR114350A1 (ru) |
AU (1) | AU2019216257A1 (ru) |
BR (1) | BR112020015173A2 (ru) |
CA (1) | CA3089080A1 (ru) |
CL (2) | CL2020001948A1 (ru) |
CO (1) | CO2020010270A2 (ru) |
EA (1) | EA202091739A1 (ru) |
IL (1) | IL275880A (ru) |
MX (1) | MX2020007876A (ru) |
SG (1) | SG11202006722RA (ru) |
TW (1) | TWI815856B (ru) |
WO (1) | WO2019152474A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020008086A (es) | 2018-01-30 | 2021-02-15 | Apnimed Inc Delaware | Metodos y composiciones para tratar la apnea del sue?o. |
US20220411821A1 (en) * | 2019-10-28 | 2022-12-29 | University Of Florida Research Foundation, Incorporated | Gene therapy vectors |
JP2023506030A (ja) * | 2019-12-16 | 2023-02-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | ジストロフィン関連タンパク質複合体(dapc)を回復および維持するための組成物および方法 |
CN116348149A (zh) * | 2020-06-15 | 2023-06-27 | 全国儿童医院研究所 | 用于肌营养不良症的腺相关病毒载体递送 |
CN115996758A (zh) | 2020-06-19 | 2023-04-21 | 吉尼松公司 | 使sgcg在肌肉和心脏中充分表达的基因治疗表达系统 |
TW202227634A (zh) | 2020-09-08 | 2022-07-16 | 美商薩羅塔治療公司 | 表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療 |
JP2023081369A (ja) * | 2021-11-30 | 2023-06-09 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用 |
EP4198134A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262035B1 (en) * | 1998-10-01 | 2001-07-17 | University Of Iowa Research Foundation | Gene replacement therapy for muscular dystrophy |
US20100247495A1 (en) * | 2009-03-30 | 2010-09-30 | Tom Ichim | Treatment of Muscular Dystrophy |
US9303079B2 (en) * | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
-
2019
- 2019-01-30 SG SG11202006722RA patent/SG11202006722RA/en unknown
- 2019-01-30 EA EA202091739A patent/EA202091739A1/ru unknown
- 2019-01-30 EP EP19747125.3A patent/EP3746100A4/en active Pending
- 2019-01-30 AR ARP190100213A patent/AR114350A1/es unknown
- 2019-01-30 CA CA3089080A patent/CA3089080A1/en active Pending
- 2019-01-30 MX MX2020007876A patent/MX2020007876A/es unknown
- 2019-01-30 JP JP2020540722A patent/JP7361701B2/ja active Active
- 2019-01-30 BR BR112020015173-4A patent/BR112020015173A2/pt unknown
- 2019-01-30 TW TW108103617A patent/TWI815856B/zh active
- 2019-01-30 US US16/966,407 patent/US20200360534A1/en active Pending
- 2019-01-30 CN CN201980009966.2A patent/CN111818946A/zh active Pending
- 2019-01-30 KR KR1020207024618A patent/KR20200115585A/ko active Search and Examination
- 2019-01-30 AU AU2019216257A patent/AU2019216257A1/en active Pending
- 2019-01-30 WO PCT/US2019/015779 patent/WO2019152474A1/en unknown
-
2020
- 2020-07-06 IL IL275880A patent/IL275880A/en unknown
- 2020-07-24 CL CL2020001948A patent/CL2020001948A1/es unknown
- 2020-08-31 CO CONC2020/0010270A patent/CO2020010270A2/es unknown
-
2021
- 2021-11-23 CL CL2021003097A patent/CL2021003097A1/es unknown
-
2023
- 2023-10-03 JP JP2023171950A patent/JP2023171900A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3746100A4 (en) | 2021-11-17 |
SG11202006722RA (en) | 2020-08-28 |
AU2019216257A1 (en) | 2020-07-23 |
TWI815856B (zh) | 2023-09-21 |
JP2021512072A (ja) | 2021-05-13 |
CL2020001948A1 (es) | 2020-10-09 |
BR112020015173A2 (pt) | 2020-12-29 |
AR114350A1 (es) | 2020-08-26 |
EP3746100A1 (en) | 2020-12-09 |
MX2020007876A (es) | 2020-12-03 |
JP7361701B2 (ja) | 2023-10-16 |
CO2020010270A2 (es) | 2020-11-20 |
WO2019152474A9 (en) | 2020-08-27 |
IL275880A (en) | 2020-08-31 |
CL2021003097A1 (es) | 2022-07-15 |
US20200360534A1 (en) | 2020-11-19 |
CN111818946A (zh) | 2020-10-23 |
WO2019152474A1 (en) | 2019-08-08 |
TW201934751A (zh) | 2019-09-01 |
KR20200115585A (ko) | 2020-10-07 |
JP2023171900A (ja) | 2023-12-05 |
CA3089080A1 (en) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091739A1 (ru) | Генная терапия против тазово-плечевой мышечной дистрофии типа 2c | |
EA201992201A1 (ru) | Доставка специфического для мышц микродистрофина векторами аденоассоциированного вируса для лечения мышечной дистрофии | |
MX2018014152A (es) | Composiciones y métodos para tratar la enfermedad de huntington. | |
PH12019500068A1 (en) | Novel adeno-associated virus capsid proteins | |
MX2017006216A (es) | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). | |
MX2018012604A (es) | Administracion de vectores del virus adenoasociado de microdistrofina para tratar la distrofia muscular. | |
CL2020003289A1 (es) | Suministro en vector del virus adeno-asociado de micro-distrofina específica de músculos para tratar la distrofia muscular | |
EA201692206A1 (ru) | Векторы на основе aav для генной терапии в сетчатке и cns | |
MX2018007234A (es) | Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal. | |
MX366343B (es) | Terapia genetica. | |
PH12020500643A1 (en) | Anti-ngf antibodies and methods thereof | |
WO2020123645A8 (en) | Combination therapy for treating muscular dystrophy | |
MX2016001204A (es) | Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo. | |
ZA201803080B (en) | Methods of treating muscular dystrophy | |
MX2021004154A (es) | Transgen de codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 3 (pfic3). | |
MX2021005435A (es) | Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2). | |
MX2018012545A (es) | Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. | |
EA201992426A1 (ru) | Композиции и способы лечения синдрома идиопатической гиперактивности мочевого пузыря и гиперактивности детрузора | |
MX2021014337A (es) | Vectores de genoterapia para osteopetrosis maligna infantil. | |
MA42736A1 (fr) | Méthodes de traitement de la dystrophie musculaire | |
EA201892338A1 (ru) | Доставка микродистрофина вектором на основе аденоассоциированного вируса для лечения мышечной дистрофии | |
EA202190513A1 (ru) | Композиции и способы для лечения пигментного ретинита | |
MX2015007650A (es) | Tratamiento de retinitis pigmentosa. | |
EA202190155A1 (ru) | Продукты на основе рекомбинантных аденоассоциированных вирусов и способы для лечения тазово-плечевой мышечной дистрофии типа 2а | |
EA202190054A1 (ru) | Доставка специфичного для мышц микродистрофина с помощью вектора на основе аденоассоциированного вируса для лечения мышечной дистрофии |